Evidence Vault

How RegenMed Circles Enable Clinically and Statistically Significant PNS ProtocolsPeripheral Nerve Stimulation (PNS) is transforming the landscape of pain management. Once seen as a last resort for intractable neuropathic pain, it now stands at the forefront of non-opioid, precision-based interventions. Yet, despite its promise, PNS has long been held back by one fundamental gap: the inability to reliably predict which patients will benefit, and under which stimulation parameters. Clinical success has often relied on trial-and-error rather than science. RegenMed Circles changes that paradigm.Closing the Evidence Gap with Circles RegenMed Circles is a real-world evidence (RWE) platform designed to bring scientific rigor and statistical power to PNS therapy. By standardizing observational protocols, integrating validated Patient-Reported Outcome Measures (PROMs), and aligning with payer-recognized ICD-10 indications, Circles enables a new generation of PNS research — one that is clinically meaningful, reproducible, and regulatory-grade.Circles moves beyond empirical feedback to structured, data-driven insights. It systematically collects pain intensity, functional outcomes, psychological metrics, and opioid utilization data across diverse populations, allowing clinicians and manufacturers to identify what truly drives long-term success.Implementing Clinically and Statistically Significant PNS ProtocolsOur recently published White paper proposes three important Observational Protocols (OPs) for PNS therapy — each designed to address high-impact clinical challenges and generate evidence suitable for coverage expansion:Post-Amputation Pain: Validates early PNS intervention as a prophylactic, opioid-sparing therapy to prevent phantom limb pain.Genicular Nerve Stimulation: Measures pain relief and functional restoration in chronic knee pain, linking PROMs such as WOMAC and KOS-ADL to payer-relevant outcomes.Postherpetic Neuralgia**: Evaluates durable efficacy of permanent PNS implants in severe neuropathic pain, with a focus on quality of life and sleep interference metrics.Each OP leverages Circles’ architecture to achieve clinically and statistically significant results. By standardizing inputs and outputs across multi-center sites, Circles delivers the statistical power necessary to draw credible conclusions — transforming individual case studies into population-level insight.From Empirical Practice to Predictive PrecisionThe future of PNS lies not just in better devices, but in better data. Circles integrates anatomical, psychological, and outcome data to inform predictive models for stimulation optimization. This shift from reactive to predictive programming aligns PNS therapy with modern precision medicine standards.By embedding computational modeling, validated PROMs, and longitudinal tracking, Circles enables clinicians to personalize therapy while giving payers and regulators the reproducible evidence they demand. The result: safer, more effective, and financially sustainable PNS care.A Platform for Clinical, Regulatory, and Market SuccessIn a market projected to more than double by 2033, RegenMed Circles positions stakeholders to lead. It provides manufacturers with evidence for FDA and CMS alignment, clinicians with actionable insights, and payers with proof of value. By uniting clinical outcomes with compliance integrity, Circles builds a foundation for scalable, non-opioid pain care.ConclusionRegenMed Circles turns the promise of PNS into predictive precision. By designing and executing clinically valid, statistically robust observational protocols, it bridges the gap between innovation and validation — unlocking the full therapeutic and commercial potential of peripheral nerve stimulation.

Circle Datasets_Principal Characteristics

The Future of Evidence-Based Peptide Use: Circles Data StrategyPeptide therapeutics are reshaping modern medicine, offering targeted treatments for conditions ranging from metabolic disorders to aesthetic concerns. These short chains of amino acids function as hormones, neurotransmitters, and signaling molecules, giving them a unique precision in interacting with the body’s receptors. This precision has driven explosive market growth, projected to reach USD 84 billion by 2034, with North America leading and Asia Pacific showing the fastest expansion.However, the promise of peptides is constrained by the limitations of traditional randomized controlled trials. While RCTs remain the gold standard for regulatory approval, their narrow inclusion criteria produce homogenous datasets that fail to represent real-world patient diversity. Older adults, patients with multiple comorbidities, and diverse ethnic groups are often excluded — leaving critical gaps in understanding how peptides perform across broad populations. Furthermore, RCTs rarely provide long-term data, undermining confidence in durability, safety, and patient-reported outcomes over years of use.Data fragmentation compounds this issue. Manual spreadsheets and siloed tools lead to inconsistent, incomplete, and error-prone information, which slows clinical innovation and complicates payer or regulatory decisions. The peptide industry urgently needs a new paradigm: structured, longitudinal, verifiable real-world evidence (RWE).Circles: A Strategic Solution RegenMed’s Circles platform delivers a scalable approach to collect and validate high quality RWE. By combining physician-facing inCytes™ and patient-facing Benchmarc™ platforms, Circles aggregates standardized datasets without interrupting normal clinical flow. They produce FDA-compliant, auditable datasets that can inform regulatory submissions, post-market surveillance, and payer negotiations.The benefits extend to multiple stakeholders. Pharmaceutical and biotech companies can sponsor Circles to generate evidence for new indications, demonstrate long-term value, and refine treatment protocols. Clinicians gain insights to optimize care and monetize their expertise while positioning themselves as thought leaders. Payers and regulators gain confidence in cost-effectiveness and safety, while patients receive more effective, personalized peptides-based therapies.Applications and Use CasesCritical areas for peptide RWE include metabolic disorders, where GLP-1 receptor agonists like semaglutide revolutionize weight loss and diabetes care; sports medicine and injury recovery, where BPC-157 accelerates healing; and anti-aging/aesthetics, where compounds like GHK-Cu improve skin elasticity and appearance.Specific Circle Datasets — for instance, correlating outcomes over two years of BPC-157 effects on ligament healing – can materially help close scientific knowledge gaps and support clinical decisions.The peptide therapeutics market is also evolving alongside manufacturing innovations such as continuous production methods that reduce waste and costs. As synthesis accelerates, new peptides will reach clinics faster, amplifying the need for robust real-world validation. Without such evidence, promising treatments risk delayed adoption or regulatory challenges.The Path ForwardEmbracing Circles-based RWE is more than a competitive edge — it’s a strategic imperative. By closing the gap between controlled trials and real-world practice, Circles create a dynamic feedback loop that informs clinical decisions, accelerates innovation, and drives commercial success. For patients, this means safer, more effective therapies tailored to their needs. For the industry, it signals a shift from simply selling molecules to delivering comprehensive, evidence-backed solutions. Those who adopt this model early will define the future of peptide therapeutics.

Real-World Evidence: Unlocking the Full Potential of MSC TherapyMesenchymal Stem Cells (MSCs) represent one of the most versatile and promising tools in regenerative medicine. Their ability to modulate the immune system, reduce inflammation, and orchestrate tissue repair has led to investigations across a wide spectrum of conditions — from osteoarthritis and autoimmune disease to pioneering neurological applications.Yet despite this therapeutic promise, clinical adoption of MSCs has been slowed by a critical barrier: evidence.The Challenge: Evidence Gaps in Regenerative MedicineRandomized controlled trials (RCTs) have long been the gold standard for clinical research. They are designed to minimize bias and deliver clear results in highly controlled settings.But for regenerative therapies, especially cell-based interventions, RCTs often fall short.Short timeframes limit the ability to capture long-term outcomes in chronic or progressive conditions.Strict inclusion criteria mean that many real-world patients — those with comorbidities or complex disease patterns — are excluded.High costs make it difficult to run large-scale, long-duration studies necessary to validate MSC durability.As a result, key questions remain unanswered: Which MSC sources perform best? What dosing regimens deliver sustainable results? How do outcomes differ across patient subgroups?The Solution: Real-World Evidence (RWE)Real-world evidence, derived from data collected during routine clinical practice, offers a transformative way forward. Unlike RCTs, RWE can:Capture outcomes over long time horizons, aligning with the chronic nature of many conditions MSCs target.Reflect the diversity of real clinical populations, not just highly selected trial cohorts.Provide practical insights into dosing, protocols, and durability that matter in day-to-day practice.Regulators, payers, and clinicians alike are increasingly turning to RWE to inform decisions. For regenerative medicine, it is not just complementary to traditional trials — it is essential.How RegenMed Circles Advances MSC EvidenceAt RegenMed, we’ve developed the Circles platform to address the unique challenges of MSC research and care. Circles are physician-led, collaborative frameworks designed to generate validatable, clinically meaningful RWE with minimal burden on providers and patients.Key features include:Structured data capture: Standardized observational protocols ensure clinical depth and comparability.Patient engagement: Tools like Benchmarc™ integrate patient-reported outcomes into the dataset.Collaboration across sites: Physicians pool outcomes data, achieving statistical power and generalizability.Physician ownership: Providers retain control and value from the data they generate.The result is high-quality, auditable datasets that not only advance clinical understanding but also inform regulators, support reimbursement, and accelerate adoption of MSC therapies.Looking AheadThe global MSC market is projected to reach $7.2 billion by 2030, reflecting the immense promise of these therapies. But to fulfill that promise, evidence generation must keep pace with innovation.By combining physician expertise, patient engagement, and rigorous data frameworks, RegenMed Circles is helping to close the evidence gap. Together, we can move MSC therapy from potential to practice — and set the standard for how regenerative medicine proves its value in the real world.Сontact usDownload the White Paper "Circles For Mesenchymal Stem Cell Care And Research", Sept 2025